AHA 2022 eBook

Dec 14, 2022

ABOUT THE CONTRIBUTORS

Author

Rebecca Shover

View all posts

MORE FROM AHA 2022

PCSK9 Monoclonal Antibody Provides ‘Significant and Durable’ Decrease in LDL-C

Nov 15, 2022

VICTORION-INCEPTION: Inclisiran Immediately After ACS for Secondary Prevention

Nov 15, 2022

ORION-3: Long-Term Inclisiran Safe & Feasible

Nov 15, 2022

Health Informatics Approach to Investigation of FH

Nov 03, 2022

Efficacy and Safety of Inclisiran: Pooled Analysis

Nov 03, 2022

PCSK9 & LDL-C Reduction in Response to RNAi Therapeutic Inclisiran

Nov 02, 2022

AHA 2022

Test Your AHA Knowledge!

Baseline Cholesterol Biomarkers Impact CV Risk in Elderly Patients

Individuals with hypercholesterolemia who had higher levels of campesterol experienced significantly fewer cardiovascular events (CVEs), according to findings from the...

Returning Secondary Findings Related to Hypercholesterolemia Has Clinical Benefits

Limited research has been done on outcomes after the return of secondary findings in large-scale sequencing projects. To assess this...

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Follow Us

AHA 2022

AHA 2022 eBook

Author

ABOUT THE CONTRIBUTORS

Author

MORE FROM AHA 2022

AHA 2022

PW Weekly Newsletters

MORE FROM AHA 2022

Stay connected to the latest news with Physician’s Weekly